Siegfried Holding AG (SFZN) AI Stock Analysis

• Market Cap: $3.43B
• Dividend Yield: 0.51%
• Average Volume (3M): 70.40K
• Price to Earnings (P/E): 21.6
• Beta (1Y): 0.93
• Revenue Growth: 0.77%
• EPS Growth: 16.70%
• Country: CH
• Employees: 3,886
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.50
• Shares Outstanding: 45,230,000
• 10 Day Avg. Volume: 70,481
• 30 Day Avg. Volume: 70,404
• PEG Ratio: -0.31
• Price to Book (P/B): 4.33
• Price to Sales (P/S): 3.28
• P/FCF Ratio: -352.04
• Enterprise Value/Market Cap: 1.27
• Enterprise Value/Revenue: 3.36
• Enterprise Value/Gross Profit: 13.08
• Enterprise Value/Ebitda: 15.12
• 1Y Price Target: $101.44
• Price Target Upside: 36.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: CHF80.00 ▲(7.38% Upside)

Siegfried Holding AG's strong financial performance, particularly its robust balance sheet and profitability, is a significant strength. However, the technical analysis indicates bearish momentum, and the valuation suggests the stock may be overvalued. These factors contribute to a moderate overall stock score.

Positive Factors

Strong Balance Sheet

A debt-free balance sheet enhances financial stability, providing flexibility for strategic investments and shielding against economic downturns.

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategy, supporting long-term expansion and profitability.

Profitability

High profitability margins reflect efficient operations and cost management, ensuring sustainable earnings and competitive advantage.

Negative Factors

Negative Free Cash Flow

Negative free cash flow can strain liquidity, limiting the ability to fund operations and growth initiatives without external financing.

High Capital Expenditures

High capital expenditures may impact cash reserves, necessitating careful management to avoid financial strain and ensure future growth.

Bearish Technical Momentum

While not a fundamental factor, prolonged bearish momentum can affect investor sentiment, potentially impacting capital raising and market perception.

Siegfried Holding AG Business Overview & Revenue Model

Company Description

Siegfried Holding AG (SFZN) is a Swiss-based pharmaceutical company that specializes in the development and production of active pharmaceutical ingredients (APIs) and finished dosage forms. Operating primarily in the pharmaceutical and biotechnology sectors, Siegfried provides a wide range of services including contract manufacturing, formulation development, and regulatory support. The company serves clients across the globe, focusing on both generic and innovative medicines, while maintaining high standards of quality and compliance in its manufacturing processes.

How the Company Makes Money

Siegfried Holding AG generates revenue through multiple key streams, primarily by offering contract manufacturing services to pharmaceutical companies, which includes the production of APIs and finished dosage forms. The company also earns revenue from the development and sale of its own proprietary products. Significant partnerships with major pharmaceutical companies enhance its revenue through long-term contracts and collaborations for drug development and manufacturing. Additionally, Siegfried capitalizes on its expertise in regulatory affairs, which allows it to charge for consulting services related to drug approval processes. The company's commitment to quality and compliance, alongside its global footprint, contributes to its ability to attract and retain high-value clients, thus bolstering its earnings.

Siegfried Holding AG Financial Statement Overview

Summary

Siegfried Holding AG shows strong financial health with solid revenue growth and profitability. The balance sheet is notably strong with no debt, enhancing financial stability. However, the negative free cash flow indicates high capital expenditures that could strain liquidity if not managed carefully.

Income Statement

Siegfried Holding AG has demonstrated consistent revenue growth, with a 1.81% increase from 2023 to 2024. The gross profit margin for 2024 was 25.42%, and the net profit margin was 12.37%, showing strong profitability. The EBIT margin improved to 15.39%, and the EBITDA margin stood at 22.36%, indicating efficient core operations and cost management.

Balance Sheet

The company has a robust balance sheet with zero debt in 2024, significantly improving its debt-to-equity position. Return on Equity (ROE) was strong at 16.33% for 2024, reflecting effective equity use. The equity ratio was 50.69%, suggesting a healthy capital structure with a significant portion of assets financed by equity.

Cash Flow

The operating cash flow to net income ratio was 1.05, indicating good cash generation relative to profit. However, the free cash flow was negative at -12.07 million, reflecting significant capital expenditures. The free cash flow to net income ratio was -0.08, showing a need for improved cash retention.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.29B	1.29B	1.27B	1.23B	1.10B	845.06M
Gross Profit	332.51M	329.06M	320.41M	318.69M	239.27M	176.00M
EBITDA	287.63M	289.49M	241.22M	308.30M	213.54M	132.18M
Net Income	154.08M	160.06M	112.77M	156.49M	95.60M	60.87M
Balance Sheet
Total Assets	1.97B	1.93B	1.86B	1.79B	1.67B	1.24B
Cash, Cash Equivalents and Short-Term Investments	35.35M	39.61M	56.63M	91.62M	72.97M	54.44M
Total Debt	465.20M	490.10M	525.00M	590.00M	560.00M	377.50M
Total Liabilities	949.22M	953.81M	1.02B	1.08B	1.06B	746.62M
Stockholders Equity	1.02B	980.19M	838.24M	710.93M	608.22M	495.65M
Cash Flow
Free Cash Flow	-24.18M	-12.07M	71.51M	19.30M	-1.04M	36.15M
Operating Cash Flow	195.75M	168.78M	208.61M	134.50M	112.36M	105.28M
Investing Cash Flow	-233.09M	-190.35M	-146.86M	-103.72M	-250.10M	-69.02M
Financing Cash Flow	7.51M	3.04M	-94.75M	-10.68M	156.24M	-6.12M

Siegfried Holding AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 74.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SFZN, the sentiment is Negative. The current price of 74.5 is below the 20-day moving average (MA) of 78.40, below the 50-day MA of 81.48, and below the 200-day MA of 90.19, indicating a bearish trend. The MACD of -1.84 indicates Positive momentum. The RSI at 27.89 is Positive, neither overbought nor oversold. The STOCH value of 9.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:SFZN.

Siegfried Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LONN	71 Outperform	CHF36.90B	50.96	―	0.75%	5.93%	29.83%
GALE	70 Outperform	CHF4.36B	22.68	―	2.67%	5.84%	8.57%
BANB	64 Neutral	CHF4.03B	30.01	10.07%	1.67%	17.34%	18.15%
SFZN	63 Neutral	$3.43B	21.56	15.79%	0.51%	0.77%	16.70%
SDZ	59 Neutral	$24.19B	122.61	2.64%	1.13%	―	―
PPGN	54 Neutral	CHF810.92M	-24.76	―	―	12.03%	-19.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Siegfried Holding AG Corporate Events

Siegfried’s DINAMIQS Opens Switzerland’s First cGMP Viral Vector Facility

DINAMIQS, a Siegfried company, has inaugurated Switzerland’s first cGMP manufacturing facility for viral vectors, enhancing its capabilities in the cell and gene therapy market. This facility, located in Zurich, integrates R&D, clinical, and commercial manufacturing, and is set to strengthen Siegfried’s market position. DINAMIQS has also announced a strategic collaboration with SEAL Therapeutics to develop a gene therapy for muscular dystrophy, showcasing its commitment to advancing innovative treatments.

The most recent analyst rating on (CH:SFZN) stock is a Buy with a CHF119.00 price target. To see the full list of analyst forecasts on Siegfried Holding AG stock, see the CH:SFZN Stock Forecast page.

Siegfried Holding AG Announces Leadership Transition

Siegfried Holding AG announced a leadership change with Dr. Andreas Casutt stepping down as Chairman of the Board of Directors at the 2026 Annual General Meeting. Dr. Beat Walti, a current board member and experienced leader, is proposed as his successor. This transition is expected to continue Siegfried’s successful growth trajectory and strengthen its market position.

The most recent analyst rating on (CH:SFZN) stock is a Hold with a CHF92.00 price target. To see the full list of analyst forecasts on Siegfried Holding AG stock, see the CH:SFZN Stock Forecast page.

Siegfried AG Secures CHF 300 Million in Bond Placement

Siegfried Holding AG has successfully placed senior bonds worth CHF 300 million with a 1.3% coupon, aimed at general corporate purposes including early refinancing of bonds maturing in June 2026. This move highlights Siegfried’s robust financing capabilities and strategic flexibility, reflecting strong investor confidence in the CDMO industry and the resilience of its business model. The bonds, placed with Swiss market investors, will be listed on the SIX Swiss Exchange, further solidifying Siegfried’s financial positioning.

The most recent analyst rating on (CH:SFZN) stock is a Hold with a CHF90.00 price target. To see the full list of analyst forecasts on Siegfried Holding AG stock, see the CH:SFZN Stock Forecast page.

Siegfried Holding AG Reports Stable Half-Year Performance

Siegfried Holding AG is a global life sciences company that specializes in manufacturing pharmaceutical active pharmaceutical ingredients (APIs) and drug products, with a presence in Switzerland, Germany, Spain, France, Malta, the USA, and China. It is publicly listed on the Swiss Stock Exchange.

Siegfried Holding AG Reports Profitable Growth and Strategic Expansions in H1 2025

Siegfried Holding AG reported profitable growth in the first half of 2025, driven by strong demand for its development and manufacturing services across various markets. Despite challenges such as inflationary pressures and currency fluctuations, the company increased its profitability and confirmed its 2025 outlook, focusing on strategic expansions and technology investments to capture future growth opportunities. Siegfried’s EVOLVE+ strategy is progressing well, with expansions in sterile eye care and spray drying capacities, and new manufacturing lines for pre-filled syringes and cartridges, expected to generate future revenues. The company anticipates continued sales growth and a core EBITDA margin above 22% for 2025.

The most recent analyst rating on (CH:SFZN) stock is a Buy with a CHF102.00 price target. To see the full list of analyst forecasts on Siegfried Holding AG stock, see the CH:SFZN Stock Forecast page.